Virtual Reality Exposure Therapy in the Treatment of Alcohol Use Disorder
Launched by UNIVERSITI SAINS MALAYSIA · Apr 23, 2023
Trial Information
Current as of August 11, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring two different types of therapy to help people with alcohol use disorder—one is called acceptance and commitment therapy (ACT), and the other is virtual reality exposure therapy (VRET). The goal is to see which therapy is more effective in reducing a person's need for alcohol and helping them avoid returning to drinking after treatment. The study will involve 120 men aged 18 to 55 who have just finished a two-week detox program. Participants will be divided into three groups: one will receive VRET, another will receive ACT, and the last group will continue with standard treatment.
To be eligible for this study, participants must be hospitalized with a diagnosis of alcohol use disorder, be right-handed, and have a minimum education level of junior high school. They should also have normal eyesight. However, individuals with a history of using other drugs, mental health issues, or serious physical illnesses won't be able to participate. Throughout the study, assessments will take place at several points: right after the therapy ends, and then again at 12 weeks and 24 weeks later to track progress. This trial is not yet recruiting participants, but it aims to offer new insights into the treatment of alcohol use disorder.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Hospitalized patients diagnosed with alcohol use disorder (confirmed by the relevant diagnostic criteria of Diagnostic and Statistical Manual of Mental Disorders-V).
- • 2. Male, age 18 to 55 years old, Han nationality, junior high school education or above, right-handed (because of the difference in EEG between right-hand and left-hand).
- • 3. Those with normal eyesight (including corrected vision).
- Exclusion Criteria:
- • 1. Those with current and lifetime history of abuse of any other psychoactive substances (except tobacco).
- • 2. Those with current and lifetime history of other mental diseases.
- • 3. Those with current and lifetime history of central nervous system diseases or serious physical illnesses.
- • 4. Those who are unable to complete the EEG detection or psychological scale assessment.
- • 5. Those who are unable to cooperate with ACT or VRET, or who are seriously uncomfortable with psychotherapy.
About Universiti Sains Malaysia
Universiti Sains Malaysia (USM) is a leading research university in Malaysia, renowned for its commitment to advancing scientific knowledge and innovation in the healthcare sector. As a clinical trial sponsor, USM leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous research aimed at improving patient outcomes and addressing pressing health challenges. The university fosters collaboration among researchers, medical professionals, and industry partners, ensuring that its clinical trials are conducted with the highest ethical standards and scientific integrity. Through its dedication to excellence in research and education, USM plays a pivotal role in shaping the future of healthcare both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Mohammad Farris Iman Leong Bin Abdullah, Dr Psych
Principal Investigator
Advanced Medical and Dental Institute, Universiti Sains Malaysia (USM)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported